Literature DB >> 8428790

Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.

P K Lipponen1.   

Abstract

Two hundred and twelve archival bladder-cancer biopsy specimens were analyzed immunohistochemically analysis were correlated to established histological and quantitative prognostic factors and survival of patients during a mean follow-up period of more than 10 years. Twenty-nine percent of tumours were positive for p53 protein, and over-expression was associated with high histological grade, non-papillary growth architecture, dense inflammatory cell reaction, DNA aneuploidy, high S-phase fraction, high mitotic frequency and high SD of nuclear area. Progression in T, N and M categories was significantly related to over-expression of p53 protein. In univariate survival analysis, over-expression of p53 predicted poor outcome in the entire cohort, in papillary tumours and in muscle-invasive tumours but not in superficial tumours. In a multivariate survival analysis, over-expression of p53 oncoprotein had no independent prognostic value over clinical stage and mitotic index. The results confirm that p53 is involved in the growth regulation of bladder cancer and is certainly a subject for detailed analysis of specific mutations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428790     DOI: 10.1002/ijc.2910530304

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.

Authors:  Z Sinik; T Alkibay; O Ataoğlu; G Akyol; H Tokuçoğlu; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 3.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 5.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

6.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?

Authors:  Latife Doganay; Semsi Altaner; Selcuk Bilgi; Esat Kaya; Galip Ekuklu; Kemal Kutlu
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

7.  P53 accumulation in precursor lesions and early stages of bladder cancer.

Authors:  B J Schmitz-Dräger; C R van Roeyen; M O Grimm; C D Gerharz; K Decken; W A Schulz; H Bültel; D Makri; T Ebert; R Ackermann
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 8.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

9.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.